Table 3.
Analysis of PET Parameters Associated with PFS in Patients with De novo Stage IV
| In Patients with De novo Stage IV | ||||
|---|---|---|---|---|
| Factors | n | PFS, Months (95% CI) | P value | HR (95% CI) |
| SUVmax | ||||
| < 12.79 | 34 | 17.2 (4.0–30.4) | 0.177 | 1.475 (0.839–2.593) |
| ≥ 12.79 | 34 | 8.2 (3.9–12.4) | ||
| SUVmean | ||||
| < 5.28 | 34 | 22.7 (9.5–35.9) | 0.110 | 1.590 (0.900–2.809) |
| ≥ 5.28 | 34 | 10.7 (6.3–14.8) | ||
| MTV (mL) | ||||
| < 109.93 | 34 | 18.4 (5.6–31.2) | 0.343 | 1.320 (0.744–2.340) |
| ≥ 109.93 | 34 | 13.1 (9.0–17.1) | ||
| TLG (g) | ||||
| < 571.56 | 34 | 18.4 (2.7–34.1) | 0.214 | 1.441 (0.810–2.563) |
| ≥ 571.56 | 34 | 12.1 (9.3–14.8) | ||
| HI | ||||
| < 2.67 | 34 | 25.4 (4.6–46.2) | 0.001 | 2.821 (1.544–5.154) |
| ≥ 2.67 | 34 | 8.2 (3.1–13.3) | ||
Abbreviations: PET/CT, positron emission tomography/computed tomography; PFS, progression- free survival; HR, hazard ratio; CI, confidence interval; SUVmax, maximum standard uptake value; SUVmean, mean standard uptake value; MTV, metabolic volume measurements; TLG, total lesion glycolysis; HI, heterogeneity index.